- < General Internal Medicine
Author Correction: First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial
By sjmartinez • March 27, 2025
Shen L, Zhang Y, Li Z, Zhang X, Gao X, Liu B, Wang Y, Ba Y, Li N, Zhang R, Zhang J, Chen Y, Chen J, Huang M, Fu Y, Liu M, Liu Z, Zhao J, Li W, Wei J, Li C, Xu N, Guo Z, Cao B, Liu L, Nie P, Wan L, Sheng L, Liu Z, He Y, Gu K, Wu G, Wang W, Zhang F, Qiu W, Guo J, Ying J, Pan H, Xu H, Yuan Y, Bai Y, Wang Z, Xu J, Zhao X, Liu H, Zhang X, Dai W, Xu H, Liu M, Xie L, Tang Y, Jin J, Qu X, Fang X, Huang M, Chen H, Zheng Z, Wang Y, Wang D, Li X, Yu G, Liu H, Zhou Y, Zhong D, Zeng S, Kang M, Wang M, Gao Y, Li W, Wang Z, Zhang M, Zhang J, Li Q, Sun S, Zang A, Lin L, Xie M, Zhuang Z, Zhang T, Yao Z, Lu D, Liu W, Hu M, Wang ZM, Li B, Xia M, Zhang J, Ying X, Pardoll DM, Ji J. Author Correction: First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial. Nat Med. 2025 Mar 26. doi: 10.1038/s41591-025-03666-y. Epub ahead of print. Erratum for: Nat Med. 2025 Jan 22. doi: 10.1038/s41591-024-03450-4. PMID: 40140623.
Related Posts
Babalyan V, Hutchings N, Baghdasaryan S, Qefoyan M, Kara-Poghosyan S, Nannipieri F, Battaglia S, Solfanelli L, Varzhapetyan A, Dallakyan G, Bilezikian JP. Kinetics and concentrations[...]
Agrawal N, Norris KC. When Words Disappear-How Banning Words Imperils Health Care Communication. JAMA. 2025 Dec 10. doi: 10.1001/jama.2025.21466. Epub ahead of print. PMID: 41369925.
Wu Y, Kim J, Elshimali Y, Sarkissyan M, Vadgama JV. Retraction Note: Activation of Akt1 accelerates carcinogen-induced tumorigenesis in mammary gland of virgin and post-lactating[...]
